NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"Below is a very helpful abstract. Also note, NWBO's GBM trial will also consider adjuvant temalazoid usage in their final covariate analysis -- according to the old protocol."

I could read the article a few more times and get more out of it, but what I think I read is that the timing of TMZ administration may be critical to long term patient survival due to a negative effect on immune memory formation as currently administered, or at least as administered for these experiments.

I would like to read the article to say... that TMZ is bad in conjunction with DC therapy for GBM. But whether the article says that or not, I believe there is strong evidence to the contrary. So instead, I interpret the findings as; while TMZ is beneficial (maybe only to methylated patient group, but that is large) it could be a lot more beneficial if we can find the correct dosing and timing coordination with DC administration to avoid stunting the formation of immune memory cells. On the other hand, this is additional evidence that maybe TMZ should not be administered to the unmethylated patient population. (you may recall my harping on this question for years now Flipper).

A BFDeal!!!! This study is another big insite into the details of what is going on in DCVax therapies. Another giant step forward, potentially.

Ever spend a lot of time trying to find a lost screw or key or something in a dark space that you can barely reach.. maybe with coat hanger or something... and no luck. Ie fishing a wire across studs inside a wall... Then you finally get a tiny flashlight and contort yourself to actually get a peak into the void... and a minute later you are done.

Added knowledge like this is golden. Kudos to the people doing that work. I hope that such knowledge can be put to work after the fact in trials like NW's trials. So much is learned these days in the length of a trial... they may have to come up with new policies to accommodate that fact.

Immunotherapies are nacient compared to chemotherapies... so they should not be judged upon current efficacy alone. Findings like this will improve the efficacy for immunotherapies continually for decades, whether it be Celldex's or IMUC's or AGEN's or NWBO's. I think that should be a consideration in approvals.